Search for a command to run...

Timestamps are as accurate as they can be but may be slightly off. We encourage you to listen to the full context.
In this episode, Joel Kocher, the 70-year-old CEO and Co-Founder of Humann, reveals how he built a $200M cardiovascular health company around the "miracle molecule" nitric oxide. (03:00) After retiring in his forties and experiencing a dramatic decline in energy, Kocher discovered nitric oxide research from the University of Texas and transformed his life - and millions of others. (05:00) He shares his journey from Dell's number two executive to building a science-backed supplement empire, explaining why most people fundamentally misunderstand heart health and how clinical trials became his competitive edge. The conversation dives deep into leadership lessons from working alongside Michael Dell and Steve Jobs, his framework for sustained growth that landed Humann on the Inc. 5000 list ten consecutive times, and why focus and patience matter more than speed in building lasting businesses.
Joel Kocher is the 70-year-old CEO and Co-Founder of Humann, a $200M cardiovascular health company built around nitric oxide science. Before founding Humann, he served as the number two executive at Dell during its explosive growth phase, helping scale the company from $100M to $1.5B in revenue in just one year. He has led four public companies, two with revenues in the billions, and was personally mentored by tech legends Michael Dell and Andy Grove. After retiring in his forties and experiencing health decline, he discovered nitric oxide research and partnered with the University of Texas to commercialize breakthrough cardiovascular health solutions.
Kocher waited seven years before entering retail, saying no to Walmart repeatedly until he was 100% confident in product velocity. (76:00) He emphasized that entrepreneurs must establish brand trust and proven sell-through rates before pursuing retail partnerships. The lesson is profound: retailers don't care about your story, only your numbers. "Don't raise money too early, don't go to retail too early - make sure you build the brand and you're 100% confident of the velocity off the shelf before you ever put it in a retailer," he explains. This patient approach allowed Humann to maintain power in retail relationships rather than being controlled by buyers.
Kocher personally interviews every single hire, even at a $200M company, looking specifically for people who want to "change the world." (57:00) He warns that hiring people who just want a job will kill your company, stating "if you're a 20 employee company and have five of those, you're dead." His screening process includes bringing candidates' partners to dinner to understand their true character. The practical application: spend more time on hiring than any other CEO activity, because you are who you hire and people largely don't transform after joining.
Despite opportunities to expand into other supplement categories, Humann remains laser-focused on cardiovascular health. (40:00) Kocher believes "focus wins" and warns against the temptation to chase every market opportunity. When asked about expanding into creatine or electrolytes, he firmly maintains their narrow and deep approach. This focus allowed them to become experts in their field and build unassailable competitive advantages through clinical trials and scientific partnerships. The lesson: resist the urge to diversify until you've completely dominated your core market.
Kocher's philosophy centers on being "impatiently patient" - having urgency while doing things right rather than fast. (48:00) He explains that companies fail because leaders double down on what worked instead of adapting to new conditions. "What got you here never gets you there" is his core operating principle. He emphasizes that the only constant is change, and leaders must have the capacity to adapt constantly while maintaining conviction in their mission. This mentality enabled Humann's ten consecutive years on the Inc. 5000 list.
Kocher introduces his concept of "talent ratio" - the relationship between revenue growth and talent acquisition. (72:00) In high-growth companies, this ratio typically shrinks because talent can't be hired fast enough to match revenue growth, diluting company capability. He argues this is the best predictor of future performance and requires CEO obsession. The practical application: in hyper-growth phases, hiring must be your primary focus because diluting talent relative to revenue is the fastest way to stall growth and lose competitive advantage.